Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data

Novo Nordisk's positive results on oral semaglutide 25 mg in treating obesity, showcasing efficacy comparable to injectable semaglutide, are significant for biotech/pharma. This data supports the potential of an oral alternative, reducing patient burden and expanding market reach, with implications for drug development strategies and commercial opportunities.